» Articles » PMID: 27882721

Survival of Patients with Metastatic Leiomyosarcoma: the MD Anderson Clinical Center for Targeted Therapy Experience

Abstract

Advanced stage leiomyosarcoma (LMS) is incurable with current systemic antitumor therapies. Therefore, there is clinical interest in exploring novel therapeutic regimens to treat LMS. We reviewed the medical records of 75 consecutive patients with histologically confirmed metastatic LMS, who had been referred to the Clinical Center for Targeted Therapy at MD Anderson Cancer Center. To lay the foundation for potential phase I trials for the treatment of advanced LMS, we analyzed tumor response and survival outcome data. The frequent hotspot gene aberrations that we observed were the TP53 mutation (65%) and RB1 loss/mutation (45%) detected by Sequenom or next-generation sequencing. Among patients treated with gene aberration-related phase I trial therapy, the median progression-free survival was 5.8 months and the median overall survival was 15.9 months, significantly better than in patients without therapy (1.9 months, P = 0.001; and 8.7 months, P = 0.013, respectively). Independent risk factors that predicted shorter overall survival included hemoglobin <10 g/dL, body mass index <30 kg/m , serum albumin <3.5 g/dL, and neutrophil above upper limit of normal. The median survivals were 19.9, 7.6, and 0.9 months for patients with 0, 1 or 2, and ≥3 of the above risk factors, respectively (P < 0.001). A prognostic scoring system that included four independent risk factors might predict survival in patients with metastatic LMS who were treated in a phase I trial. Gene aberration-related therapies led to significantly better clinical benefits, supporting that further exploration with novel mechanism-driven therapeutic regimens is warranted.

Citing Articles

A Case of DEB-TACE Combined with Anlotinib for Treatment of Liver Metastasis from Retroperitoneal Leiomyosarcoma.

Cui H, Xu Q, Han Z, Zhang S J Hepatocell Carcinoma. 2025; 12:459-465.

PMID: 40051557 PMC: 11884410. DOI: 10.2147/JHC.S502611.


Case report: Highly response to low-dose brachytherapy in recurrent retroperitoneal leiomyosarcoma with FANCD2 frameshift mutation: a unique case study.

Liu X, Zhao J, Di X, Cao G, Zhang H, Wang J Front Oncol. 2024; 14:1339955.

PMID: 38634045 PMC: 11021697. DOI: 10.3389/fonc.2024.1339955.


PD-1 Inhibition in metastatic high tumour mutational burden (TMB) leiomyosarcoma with clinicopathological correlates.

Pandita D, Dave M, Schulte B BMJ Case Rep. 2023; 16(11).

PMID: 37977843 PMC: 10660649. DOI: 10.1136/bcr-2023-256697.


Novel metabolomics-biohumoral biomarkers model for predicting survival of metastatic soft-tissue sarcomas.

Vignoli A, Miolo G, Tenori L, Buonadonna A, Lombardi D, Steffan A iScience. 2023; 26(10):107678.

PMID: 37752948 PMC: 10518687. DOI: 10.1016/j.isci.2023.107678.


B-cell lymphoma 2 family members and sarcomas: a promising target in a heterogeneous disease.

Oliveira R, Gama J, Casanova J Explor Target Antitumor Ther. 2023; 4(4):583-599.

PMID: 37720343 PMC: 10501895. DOI: 10.37349/etat.2023.00154.


References
1.
Helman L, Meltzer P . Mechanisms of sarcoma development. Nat Rev Cancer. 2003; 3(9):685-94. DOI: 10.1038/nrc1168. View

2.
Grothey A, Sargent D, Goldberg R, Schmoll H . Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004; 22(7):1209-14. DOI: 10.1200/JCO.2004.11.037. View

3.
Serrano C, George S . Leiomyosarcoma. Hematol Oncol Clin North Am. 2013; 27(5):957-74. DOI: 10.1016/j.hoc.2013.07.002. View

4.
Bathan A, Constantinidou A, Pollack S, Jones R . Diagnosis, prognosis, and management of leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013; 25(4):384-9. DOI: 10.1097/CCO.0b013e3283622c77. View

5.
Tap W, Jones R, Van Tine B, Chmielowski B, Elias A, Adkins D . Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet. 2016; 388(10043):488-97. PMC: 5647653. DOI: 10.1016/S0140-6736(16)30587-6. View